Systemic therapies at the end of life vary by patient and practice
Cancer · 2023
DOI: 10.1002/cncr.35053 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2023. Verfasst von Mary Beth Nierengarten. Hauptthemen laut MEDLINE: Terminal Care, Insurance, Neoplasms. Die Arbeit nennt 1 Literaturangaben.
Themen: Palliativpflege
Abstract (Originalsprache)
This news section offers Cancer readers timely information on events, public policy analysis, topical issues, and personalities. In this issue, whether or not patients with cancer at the end of life received systemic therapies depended partly on race, insurance type, and the practice where they were treated, but experts debate whether decisions based on these factors are in patients’ best interests. In addition, staging laparoscopy for patients with pancreatic cancer to help to determine the best treatment option is a valuable practice, and pirtobrutinib is effective in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma for whom prior treatments with BTK inhibition and venetoclax failed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Zitieren
APA
Nierengarten, M. B. (2023). Systemic therapies at the end of life vary by patient and practice. Cancer. https://doi.org/10.1002/cncr.35053
Vancouver
Nierengarten MB. Systemic therapies at the end of life vary by patient and practice. Cancer. 2023. doi:10.1002/cncr.35053
BibTeX
@article{Nierengarten2023,
author = {Nierengarten, Mary Beth},
title = {Systemic therapies at the end of life vary by patient and practice},
journal = {Cancer},
year = {2023},
doi = {10.1002/cncr.35053}
}
EUVIMED